Wednesday, August 10

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Three-Year Follow Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients receiving OvaStem® Procedure for Treating Primary Ovarian Insufficiency

PHOENIX, July 28, 2022 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company’s OvaStem® pilot study.  The data shows significant efficacy of the OvaStem® procedure for the treatment of medical refractory Primary Ovarian Insufficiency (POI) without any serious adverse effects and the successful birth of healthy babies.

OvaStem® is a patented outpatient clinic procedure that utilizes a patient’s own bone marrow aspirate for treatment of medical refractory POI. Below is a summary of the study’s three-year follow up data:

There were no safety related concerns at up to three years and the OvaStem® procedure resulted in an efficacy of 90% in the treated patients in terms of improvement in hormonal function and 70% in terms of delivery of healthy babies using their own eggs. Patients with POI usually only have a 5% to 10% chance of spontaneous pregnancy and must rely on donor eggs for conception via in vitro fertilization therapy. The company plans to submit a manuscript for publication in a peer reviewed journal and present the data at future fertility medicine conferences. 

“The positive three-year data from our OvaStem® pilot study is very encouraging, and we are excited to engage with practitioners on further development and translation,” said Timothy Warbington, President and CEO of the company.  “To our knowledge, this pilot study is one of the first to demonstrate the clinical efficacy of injecting bone marrow aspirate into the ovaries using a minimally invasive outpatient procedure, thereby repairing, remodeling and improving the function.  We believe as we further develop the OvaStem® program there is great potential to help patients with POI to conceive and deliver babies using eggs from their own ovaries without having to use surrogacy or donor eggs. Despite all on-going research, there is no FDA approved treatment for POI.”

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com

Forward Looking Statements

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

SOURCE Creative Medical Technology Holdings, Inc.



Source link